|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-4-7
|
|
pubmed:abstractText |
Urinary liver-type fatty-acid-binding protein (L-FABP) is a useful clinical marker in the monitoring of chronic kidney disease (CKD) associated with tubulointerstitial damage. Statins have been shown to be effective in the treatment of renal disease. The aim of the present study was to determine whether pitavastatin, a newly developed statin, modulates the urinary L-FABP levels in normolipidemic patients with CKD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-8095
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2006 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
82-6
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16534182-Adult,
pubmed-meshheading:16534182-Biological Markers,
pubmed-meshheading:16534182-Cholesterol,
pubmed-meshheading:16534182-Chronic Disease,
pubmed-meshheading:16534182-Fatty Acid-Binding Proteins,
pubmed-meshheading:16534182-Female,
pubmed-meshheading:16534182-Humans,
pubmed-meshheading:16534182-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:16534182-Kidney Diseases,
pubmed-meshheading:16534182-Male,
pubmed-meshheading:16534182-Proteinuria,
pubmed-meshheading:16534182-Quinolines,
pubmed-meshheading:16534182-Triglycerides
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease.
|
|
pubmed:affiliation |
Department of Internal Medicine, Shinmatsudo Central General Hospital, Chiba, Japan.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
